Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients

Long wait times for kidney transplant and the high risk of mortality on dialysis have prompted investigation into strategies to increase organ allocation and decrease discard rates of potentially viable kidneys. Organs from hepatitis C virus (HCV) antibody positive donors are often rejected; nearly...

Full description

Saved in:
Bibliographic Details
Published in:Hemodialysis international 2018-04, Vol.22 (S1), p.S71-S80
Main Authors: Sise, Meghan E., Chute, Donald F., Gustafson, Jenna L., Wojciechowski, David, Elias, Nahel, Chung, Raymond T., Williams, Winfred W.
Format: Article
Language:English
Subjects:
Direct Acting Antivirals
Hepatitis C
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long wait times for kidney transplant and the high risk of mortality on dialysis have prompted investigation into strategies to increase organ allocation and decrease discard rates of potentially viable kidneys. Organs from hepatitis C virus (HCV) antibody positive donors are often rejected; nearly 500 HCV‐infected kidneys are discarded annually in the United States. Due the opioid epidemic, the number of HCV‐infected donors has increased because of a rise in both new HCV infections and drug‐related deaths. In the past 5 years, HCV has been transformed into a curable illness with direct‐acting antiviral therapies (DAAs) that are effective in >95% of patients treated and are extremely well tolerated. Recent data has shown several direct‐acting antiviral combinations are safe and effective after kidney transplant, and can achieve the same high cure rate seen in the general population and without increasing the rate of acute rejection. Because of this, strategies to decrease discard of HCV‐infected organs have been devised. Two recent studies have transplanted HCV‐uninfected dialysis patients with kidneys from donors actively infected with HCV; recipients were treated with DAA in the peri‐transplant period. More research is needed to determine the safety and efficacy of this approach, but it has the potential to dramatically increase the donor pool of available kidneys, shorten waitlist times and ultimately decreases mortality in patients waiting for kidney transplant.
ISSN:1492-7535
1542-4758
DOI:10.1111/hdi.12650